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The cholesterol absorption inhibitor ezetimibe can signiﬁcantly reduce plasma cholesterol concentrations by inhibiting the
Niemann-Pick C1-like 1 protein (NPC1L1), an intestinal sterol inﬂux transporter that can actively facilitate the uptake of
cholesterol for intestinal absorption. Unexpectedly, ezetimibe treatment also induces a complete resistance to cholesterol gallstone
formation and nonalcoholic fatty liver disease (NAFLD) in addition to preventing hypercholesterolemia in mice on a Western diet.
Because chylomicrons are the vehicles with which the enterocytes transport cholesterol and fatty acids into the body, ezetimibe
could prevent these two most prevalent hepatobiliary diseases possibly through the regulation of chylomicron-derived cholesterol
and fatty acid metabolism in the liver. It is highly likely that there is an intestinal and hepatic cross-talk through the chylomicron
pathway. Therefore, understanding the molecular mechanisms whereby cholesterol and fatty acids are absorbed from the intestine
could oﬀer an eﬃcacious novel approach to the prevention and the treatment of cholesterol gallstones and NAFLD.
1.Introduction
The small intestine is a unique organ providing dietary
and reabsorbed biliary cholesterol to the body [1–3]. High
plasma total and low-density lipoprotein (LDL) cholesterol
concentrations are an important risk factor for cardiovascu-
lar diseases. The restriction of dietary calories, cholesterol,
and saturated fat has been used as the primary initial
therapeutic modality for the treatment of patients with dys-
lipidemia [4]. However, the reduction of dietary cholesterol
is frequently not associated with a signiﬁcant decrease in
circulating LDL cholesterol levels, despite signiﬁcant restric-
tions in dietary intake. Therefore, pharmacological inter-
vention aimed to reduce intestinal cholesterol absorption is
potentially an eﬀective way of lowering plasma total and
LDL cholesterol concentrations [2]. The use of cholesterol
absorption inhibitors for treating hypercholesterolemia has
a long history, and several classes of compounds such as
hydrophilic bile acid ursodeoxycholic acid (UDCA) [2], the
bile acid sequestrants, speciﬁc lipase inhibitors, the intestinal
acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors [5,
6], and cholesterol ester transfer protein inhibitors [7]h a v e
been developed, and some of them are currently being
evaluated in clinical trials. Recently, the discovery and devel-
opment of ezetimibe, a novel, selective, and potent inhibitor
that eﬀectively blocks intestinal absorption of dietary and
biliary cholesterol, opened a new door to the treatment of
hypercholesterolemia [2, 8–11]. Ezetimibe, which can be
administered either as monotherapy or in combination with
statins, has been shown to be a safe and eﬃcacious treatment
for hypercholesterolemia, potentially enabling more patients
to reach recommended LDL cholesterol standards set by the
National Cholesterol Education Program Adult Treatment
Panel III guidelines [12].
U n e x p e c t e d l y ,i tw a sf o u n dt h a te z e t i m i b et r e a t m e n t
can induce a complete resistance to cholesterol gallstone2 Journal of Lipids
formation [13] and nonalcoholic fatty liver disease (NAFLD)
in addition to its eﬀect on hypercholesterolemia in mice
on a Western diet [14]. Furthermore, ezetimibe can pre-
vent gallstones by eﬀectively reducing intestinal cholesterol
absorption and biliary cholesterol secretion and protecting
gallbladder motility function by desaturating bile in mice.
Treatment with ezetimibe also promotes the dissolution of
gallstones by forming an abundance of unsaturated micelles
in bile. Furthermore, ezetimibe signiﬁcantly reduces biliary
cholesterol saturation and retards cholesterol crystallization
in biles of patients with gallstones [15]. It is also found
that ezetimibe could prevent fatty liver by reducing hepatic
lipogenesis in mice on a high-fat diet and attenuating diet-
induced insulin resistance, a state known to drive hepatic
lipogenesis through elevated circulating insulin levels [16].
Therefore, it is highly likely that ezetimibe could be a novel
approach to reduce biliary cholesterol content and hepatic
triglyceride accumulation, and thus a promising strategy for
preventing or treating cholesterol gallstones and NAFLD, by
inhibiting intestinal cholesterol absorption [15].
I nt h i sp a p e r ,w ew i l lr e v i e wr e c e n tp r o g r e s si nu n d e r -
standing the biochemical and physical-chemical mecha-
nisms, whereby ezetimibe could prevent or treat cholesterol
gallstones and NAFLD, the two most prevalent hepatobiliary
diseases that constitute a considerable health care burden in
the USA.
2.Chemistry andPharmacology of Ezetimibe
Ezetimibe (SCH 58235), 1-(4-ﬂuorophenyl)-(3R)-[3-(4-ﬂu-
orophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-
azetidinone, and an analog, SCH 48461, (3R)-(3-Phenyl-
propyl)-1, (4S)-bis(4-methoxyphenyl)-2-azetidinone, are
highly selective intestinal cholesterol absorption inhibitors.
They can eﬀectively and potently prevent the absorption of
cholesterol by inhibiting the uptake and transport of dietary
and biliary cholesterol across the apical membrane of enter-
ocytes[17].Ithasbeenfoundthatthe2-azetidinonesareable
toinhibitcholesterolabsorptionatverylowdosesandinduce
signiﬁcant reductions in plasma cholesterol concentrations
in humans and in a series of diﬀerent animal models
[2, 18–20]. After oral administration, ezetimibe undergoes
rapid monoglucuronidation in enterocytes and the liver
during its ﬁrst pass. Because ezetimibe and its glucuronide
are enterohepatically recirculated, it is most likely that
they could repeatedly produce an inhibitory action on the
Niemann-Pick C1-like 1 protein (NPC1L1) on the apical
membrane of enterocytes, exhibiting multiple peaks of
serum drug concentrations with an elimination half-life
of approximately 22 hours [21]. This may explain why
ezetimibe has a longer duration of action and why its
therapeutic eﬀects persist for several days after its cessation.
These observations support the notion that once-daily
dosing should be suﬃcient for an adequate therapeutic
eﬀect. It has also been demonstrated that 12 hours after
oral administration of the glucuronide (SCH-60663),
more than 95% of the compound still can be found in
the intestine. Because the glucuronide is more potent in
inhibiting cholesterol absorption than ezetimibe, it conﬁrms
that ezetimibe acts directly in the intestine as glucuronide
[6]. Studies with [125I]-labeled ezetimibe glucuronide and
[14C]-labeled cholesterol have found that the glucuronide
could block the cholesterol uptake into the enterocytes [2]
because it is often detected in the brush border membrane,
a site predominantly associated with cholesterol uptake and
transepithelial transport. Furthermore, ezetimibe and its
analogs are relatively small molecules that may not be able
to change the physical-chemical nature of the intraluminal
environment, nor aﬀect the enterohepatic ﬂux of bile acids
[2].
A careful analysis of 399 patients receiving either
placebo- or ezetimibe-doses of 0.25, 1, 5, or 10mg once
daily found a median percentage reduction of plasma LDL
cholesterol levels of 0%, 12.7%, 14.7%, 15.8%, and 19.4%,
respectively [22]. Ten milligrams of ezetimibe daily reduces
intestinal cholesterol absorption by 54% compared with
placebo. This eﬀect is accompanied by a decrease in plasma
LDL cholesterol levels of 20%, a compensatory increase of
89% in hepatic cholesterol biosynthesis (versus placebo) and
is also associated with a decrease in the absorption of plant
sterols that are highly structurally related to cholesterol [22].
Duringezetimibetreatment,thereisamarkedcompensatory
increase in cholesterol biosynthesis in the liver, but not
in the extrahepatic organs, and an accelerated loss of
cholesterol in the feces with little or no change in the
rate of conversion of cholesterol to bile acids. Therefore,
the combined administration of the cholesterol absorption
inhibitor (ezetimibe) and the 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase inhibitors (e.g., ator-
vastatin or simvastatin) produces an enhanced reduction in
plasma total and LDL cholesterol levels, as well as provides
a complementary treatment strategy for high-risk patients,
including patients with homozygous familial hypercholes-
terolemia [23]. These results showed that ezetimibe in
combination with HMG-CoA reductase inhibitors would be
particularly eﬀective at reducing plasma cholesterol levels in
humans.
In the early studies, it was reported that ezetimibe may
not aﬀect intestinal absorption of triglycerides, fatty acids,
bile acids, or fat-soluble vitamins, including vitamins A, D,
E, and α-a n dβ-carotenes [24]. More recently, intestinal fatty
acid absorption was carefully reexamined by a sensitive and
physiologically accurate method, the sucrose polybehenate
technique in mice [25, 26]. Instead of monitoring the
appearance in plasma of digestion products from an acutely
delivered bolus of oil, fecal excretion of dietary fat is
measured by this technique and normalized to the excretion
of a nonabsorbable fat, sucrose polybehenate, incorporated
intothediet[26].Itisobservedthatonthechowdiet,dietary
fatty acid absorption is signiﬁcantly reduced from approx-
imately 95% in control mice to about 87% in ezetimibe-
treatedmice.Moreover,ezetimibetreatmentcansigniﬁcantly
reduce intestinal absorption of saturated fatty acids in a
graded manner that correlates with chain length. Thus,
intestinal absorption of palmitate (16:0) and stearate (18:0)
is reduced from approximately 90% and 70% in control
miceto80%and50%inezetimibe-treatedmice,respectively.Journal of Lipids 3
Intestinal absorption eﬃciency of medium-chain saturated
fatty acids is more moderately aﬀected, possibly because
medium-chain fatty acid absorption is less dependent on
the chylomicron pathway. Myristate (14:0) absorption is
reduced by 7–10% and laurate (12:0) absorption by 4%
in ezetimibe-treated mice as compared with control mice
[26]. These experiments strongly indicate that ezetimibe can
reduceintestinalabsorptioneﬃciencyofnotonlycholesterol
but also long-chain fatty acids in mice. Additionally, it has
been found that besides plasma total and LDL cholesterol
concentrations, ezetimibe reduces liver cholesteryl ester
levels in a dose-dependent fashion in cholesterol-fed ham-
sters, rats, and monkeys by inhibiting intestinal cholesterol
absorption. However, ezetimibe does not signiﬁcantly aﬀect
plasma HDL cholesterol or triglyceride levels. It was found
fromanindirectmeasurementofchylomicronsfromplasma,
but not lymph, that cynomolgus monkeys fed a single high-
cholesterol meal and treated with an ezetimibe analogue dis-
played a signiﬁcant reduction in the chylomicron cholesterol
content,butnotinthetriglyceridecontent[27].Theseresults
suggest that it may be important to carefully investigate the
absorption and lymphatic transfer of cholesterol and fatty
acids in lymph-ﬁstula animal models. Because chylomicrons
and chylomicron remnants may be atherogenic [28], further
investigation of this phenomenon might shed more light on
the mechanism of the antiatherogenic eﬀect of ezetimibe.
It will also be important to investigate whether ezetimibe
could inﬂuence the lipid and lipoprotein composition of
chylomicrons and their physical structure, as well as their
assembly and secretion by the enterocytes into the lymph
in animals and humans. Of note is that while statins
may increase the clearance of chylomicron remnants, they
do not reduce the cholesterol content of chylomicrons.
Therefore, the combination of a statin and ezetimibe could
be highly eﬀective in reducing the atherogenic potential of
chylomicrons [29].
3. Mechanismsof EzetimibeAction on
IntestinalAbsorption of Cholesterol and
FattyAcids
Although ezetimibe reduces intestinal cholesterol absorp-
tion, it does not inﬂuence intestinal gene expression levels of
Abcg5, Abcg8, Sr-b1, and Abca1 in mice [2, 30]. Employing a
genomic-bioinformatics approach, Altmann et al. [31]i d e n -
tiﬁed transcripts containing expression patterns and struc-
tural characteristics anticipated in cholesterol transporters
(e.g., sterol-sensing and transmembrane domains, extracel-
lular signal peptides) and established a strong candidate
for the ezetimibe-sensitive cholesterol transporter, the awk-
wardly named Niemann-Pick C1-like protein 1 (NPC1L1).
NPC1L1has50%aminoacidhomologytoNPC1[31],which
is defective in the cholesterol storage disease Niemann-Pick
type C and functions in intracellular cholesterol traﬃcking
[32]. However, in contrast to NPC1 that is expressed in
many tissues [33, 34], NPC1L1 is expressed predominantly
in the gastrointestinal tract with peak expression in the
proximal jejunum. Subfractionation of brush border mem-
branes suggests that NPC1L1 is associated with the apical
membrane fraction of enterocytes. Moreover, NPC1L1 deﬁ-
cient mice show a ∼65% reduction in intestinal cholesterol
absorption (16%) compared with wild-type mice (45%).
The cholesterol absorption eﬃciency in NPC1L1 deﬁcient
mice is unaﬀected by ezetimibe or cholic acid, supporting
the presence of redundant alternative pathways [31]. These
studies strongly suggest that NPC1L1 could be an ezetimibe-
sensitive target protein and is responsible for cholesterol
uptake by the enterocyte for intestinal absorption (Figure 1)
[31].
Many of the details of how ezetimibe prevents cholesterol
absorption have been elucidated, and recently a molecular
mechanism for cholesterol uptake mediated by the NPC1L1
has been proposed. The NPC1L1 protein recycles between
the plasma membrane facing the extracellular space and
the endocytic recycling compartment [35]. If the choles-
terol concentration in the intestinal lumen is high, it is
incorporated into the plasma membrane and is sensed by
NPC1L1 that is localized on the surface of apical membrane
of the enterocytes [34]. Both NPC1L1 and cholesterol are
then internalized together through clathrin/AP2-mediated
endocytosis [36]. The clathrin-coated globular vesicles are
transported along microﬁlaments to the endocytic recy-
cling compartment where large quantities of cholesterol
and NPC1L1 are subsequently stored [36, 37]. If the
intracellular cholesterol level is low, endocytic recycling
compartment-localized NPC1L1 free of cholesterol moves
back to the plasma membrane along microﬁlaments to
transfer new cholesterol as it is absorbed by the entero-
cytes. The key role of the NPC1L1 inhibitor ezetimibe
is to prevent NPC1L1 from entering the AP2-mediated
clathrin-coated vesicles. At this stage, the endocytosis of
NPC1L1 is inhibited and cholesterol absorption is decreased
[36].
Although it has been observed that ezetimibe can reduce
intestinal fatty acid absorption in mice, the molecular
mechanism of this action is still unclear. As reviewed above,
the deletion of the Npc1l1 gene also reduces intestinal
absorption of fatty acids, especially long-chain fatty acids.
A potential mechanism may be that inhibition of intestinal
cholesterol absorption by ezetimibe could somehow inﬂu-
ence intestinal expression of genes involved in fatty acid
uptake and transport. It is well known that hydrolysis and
absorption of dietary fat (mainly triglycerides) are extremely
eﬃc i e n tp r o c e s s e s( >90%). However, it remains a matter
of debate whether intestinal fatty acid absorption occurs
solely by passive diﬀusion or also by protein-facilitated
transport. Some studies have suggested that fatty acid
transporter/cluster determinant 36 (FAT/CD36) may play
a role in intestinal fatty acid absorption [38, 39]. Thus, it
has been hypothesized that ezetimibe may have potential
inhibitory eﬀects on “protein-facilitated” absorption of fatty
acids by enterocytes [26]. As found by Western blot analysis,
protein concentrations of fatty acid transport protein 4
(FATP4) in the small intestine are signiﬁcantly reduced
by approximately 50% in ezetimibe-treated mice compared
with control mice (Figure 1), which is associated with
reduced intestinal absorption of long-chain saturated fatty4 Journal of Lipids
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Figure 1: Within the intestinal lumen, the micellar solubilization of sterols facilitates movement through the diﬀusion barrier overlying the
surface of the absorptive cells. In the presence of bile acids, large amounts of the sterol molecules are delivered to the aqueous-membrane
interface so that their uptake rate is greatly increased. The Niemann-Pick C1-like 1 protein (NPC1L1), a newly identiﬁed sterol inﬂux
transporter, is located at the apical membrane of the enterocyte and may actively facilitate the uptake of cholesterol and plant sterols by
promoting the passage of these molecules across the brush border membrane of the enterocyte. In contrast, ABCG5/G8 promote active
eﬄuxofcholesterolandplantsterolsfromtheenterocyteintotheintestinallumenforexcretion.ThecombinedregulatoryeﬀectsofNPC1L1
and ABCG5/G8 play a critical role in modulating the amount of cholesterol that reaches the lymph from the intestinal lumen. Ezetimibe
may reduce cholesterol uptake by the enterocytes through the NPC1L1 pathway, possibly a transporter-facilitated mechanism. Absorbed
cholesterol as well as some that is newly synthesized from acetate by 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) within the
enterocyte is esteriﬁed by acyl-CoA:cholesterol acyltransferase isoform 2 (ACAT2) to form cholesteryl esters. It is likely that fatty acids (FA)
and monoacylglycerol (MG) could be taken up into enterocytes by facilitated transport. With the assistance of fatty acid binding protein
4 (FABP4), fatty acids and monoacylglycerol are transported into the smooth endoplasmic reticulum (SER) where they are used for the
synthesis of diacylglycerol (DG) and then triacylglycerol (TG). Glucose is transported into the SER for the synthesis of phospholipids (PL)
through the phosphatidic acid (PA) pathway (abbreviation: α-GP, α-glycerophosphate). All of these lipids participate in the formation of
chylomicrons, a process which also requires the synthesis of apolipoprotein (APO)-B48 and the activity of microsomal triglyceride transfer
protein (MTTP). As observed in lymph, the core of the secreted chylomicrons contains triglycerides and cholesteryl esters and the surface of
the particles is a monolayer containing phospholipids, mainly phosphatidylcholine, unesteriﬁed cholesterol and apolipoproteins including
APO-B48, APO-AI, and APO-AIV. Therefore, intestinal cholesterol absorption is a multistep process that is regulated by multiple genes.
Reproduced with modiﬁcations and with permission from [50].
acids [26, 40]. It is unclear whether this inhibitory eﬀect
on intestinal FATP4 is induced by ezetimibe through a
direct or indirect action pathway. Another explanation is
that ezetimibe treatment signiﬁcantly reduces cholesterol
absorption so that the physical structure of chylomicrons
may be modiﬁed and their assembly, and/or secretion into
the lymphatics may be impaired. Because chylomicrons
are a crucial vehicle for the transfer of cholesterol and
fatty acids as triglyceride from the intestinal lumen to the
lymph, impairing their formation by reducing cholesterol
availability may induce a secondary action on fatty acid
absorption. Because of this possible mechanism of action,
it will be important to examine the physical structure of
chylomicrons and their assembly and secretion into lymph
to prove this hypothesis.
4. Physical-Chemistry of Bile, Physical
FormsofCholesterolCarrier,and
Pathophysiology of Cholesterol Gallstones
Cholesterol, phospholipids, and bile salts are three major
lipid components of bile in animals and humans [41].
Because cholesterol is virtually insoluble in an aqueous
medium such as bile, specialized transport mechanisms are
required to maintain it in solution and the mechanism for
its solubilization in bile is complex. Similarly, phospholipids
are insoluble in water and require carrier vehicles in
bile. Bile salts have the property of amphiphilicity with
both hydrophilic and hydrophobic areas of the molecules
and are soluble in aqueous solutions to varying degrees,
depending on the number and characteristics of hydroxylJournal of Lipids 5
groups and side chains, as well as the composition of
the particular aqueous solution. Bile salt monomers can
aggregate spontaneously to form simple micelles when their
concentration exceeds the critical micellar concentration
[42]. As deﬁned, a micelle is a colloidal aggregation of
molecules of an amphipathic compound (e.g., bile salt)
in which the hydrophobic portion of each molecule faces
inward and the hydrophilic groups point outward [41]. The
formation of simple micelles of bile salts alone depends
primarily on the concentration of bile salts. Thus, micelles
areformedat,butnotbelow,acriticalmicellarconcentration
of bile salts in bile, which is approximately 2mmol/L
[41]. The formation of micelles is also inﬂuenced by the
concentrations of biliary solids and counterions, by the
type of bile salt (i.e., by its degree of hydroxylation and
whether it is conjugated with taurine or glycine or not),
and by the temperature and pH of the bile. These simple
micelles (∼3nm in diameter) are small, thermodynamically
stable aggregates that are principally composed of bile
salts [43]. The cholesterol can be solubilized within the
hydrophobic center of the micelle. Also, simple micelles
of bile salts are capable of solubilizing and incorporating
phospholipids. This enables the micelles—then referred to
as mixed micelles—to solubilize at least three times the
amount of cholesterol solubilized by simple micelles. The
solubility of cholesterol in mixed micelles is enhanced when
the concentration of total lipids (bile salts, phospholipids,
and cholesterol) in bile is high. Moreover, maximal solubility
occurs when the molar ratio of phospholipids to bile salts is
between 0.2 and 0.3 [41]. Mixed micelles (∼4–8nm in diam-
eter) are large, thermodynamically stable aggregates that
are composed of bile salts, cholesterol, and phospholipids.
Their size varies depending on the relative proportion of
bile salts and phospholipids. The shape of a mixed micelle
is that of a lipid bilayer with the hydrophilic groups of
the bile salts and phospholipids aligned on the “outside”
of the bilayer, interfacing with the aqueous bile, and the
hydrophobic groups on the “inside.” Cholesterol molecules
can, therefore, be solubilized on the inside of the bilayer
away from the aqueous areas on the outside. The amount
of cholesterol that can be solubilized in micelles depends on
the relative proportions of bile salts and phospholipids, with
additional phospholipids aiding in cholesterol solubilization
[41].
Studies using techniques such as quasielastic light-
scattering spectroscopy (QLS) and electron microscopy to
investigate the physical-chemistry of model and native
bile samples have deﬁned more complex mechanisms of
cholesterol solubilization in bile [41, 44, 45]. Beside simple
and mixed micelles, biliary vesicles, nonmicellar carriers
of cholesterol, do exist in bile for the solubilization of
cholesterol. Vesicles are unilamellar spherical structures and
containphospholipids,cholesterol,andlittle,ifany,bilesalts.
Thus, vesicles (∼40 to 100nm in diameter) are substantially
larger than either simple or mixed micelles, but much
smaller than liquid crystals (∼500nm in diameter) that are
composed of multilamellar spherical structures. Vesicles are
present in large quantities in hepatic bile and are presumably
secreted by the hepatocyte [41].
Vesicles in bile have one of two distinct origins. Those
formed at the canalicular membrane of hepatocytes are
unilamellar and rich in phosphatidylcholines compared
with cholesterol (i.e., contain one cholesterol molecule per
three phosphatidylcholine molecules). Because of increasing
bile salt concentrations in the biliary tree, these vesicles
rapidly undergo structural rearrangements and are therefore
detectable only in bile specimens analyzed immediately after
collection. A second type of vesicle forms spontaneously
in bile when the capacity of mixed and simple micelles
to solubilize cholesterol is exceeded. These unilamellar or
multilamellar vesicles are cholesterol-rich, with cholesterol
content reaching as high as two cholesterol molecules per
phosphatidylcholine molecule.
When concentrations of bile salts are relatively low,
vesicles are relatively stable, especially in dilute hepatic bile.
Moreover, vesicles may transform or convert completely to
mixed micelles when bile salt concentrations in concentrated
gallbladder bile are increased. When the bile salt concen-
tration is not high enough, only some vesicles convert to
micelles. Because relatively more phospholipids than choles-
terol can be transferred from vesicles to mixed micelles, the
residual vesicles, now remodeled, may be rich in cholesterol
relative to the phospholipids. If the remaining vesicles have
a relatively low cholesterol/phospholipid ratio (<1), they are
relatively stable. However, if the cholesterol/phospholipid
r a t i oi nv e s i c l e si s>1, vesicles become increasingly unstable
[46]. These cholesterol-rich vesicles may transfer some
cholesterol to less cholesterol-rich vesicles or to micelles, or
may fuse or aggregate to form larger (∼500nm in diameter)
multilamellar vesicles that may now be termed liposomes or
liquid crystals [41]. Liquid crystals are visible by polarizing
light microscopy as lipid droplets with birefringence in the
shape of a Maltese cross. Liquid crystals are inherently
unstable and may form solid cholesterol monohydrate
crystals, which is termed cholesterol nucleation. As a result,
the nucleation of cholesterol monohydrate crystal induces a
decrease in the amount of cholesterol contained in vesicles
but not of cholesterol in micelles, supporting the concept
that vesicles could serve as the primary source of cholesterol
during cholesterol nucleation and crystallization [41].
It is well known that cholesterol cholelithiasis is a
multifactorial disease inﬂuenced by a complex interaction
of genetic and environmental factors [15, 42, 47]. Based
on recent studies on humans and mouse models, a novel
concept has been proposed that interactions of ﬁve defects
could play an important role in determining the formation
of cholesterol gallstones (Figure 2), which are considered
in terms of LITH genes (genetic defect), thermodynamics
(solubility defect), kinetics (nucleation defect), stasis (resi-
dence time defect), and lipid sources (metabolic defect) [48].
Furthermore, cholesterol gallstone formation represents a
failure of biliary cholesterol homeostasis in which the
physical-chemical balance of cholesterol solubility in bile is
disturbed [41, 42, 47]. The liver is the source of cholesterol-
supersaturated bile in the gallbladder with cholesterol gall-
stones. Thus, gallstones can be viewed in one sense as a liver
disease because some metabolic defects or a combination
of defects within the liver result in hypersecretion of biliary6 Journal of Lipids
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Figure 2: Venn diagram of ﬁve primary defects: genetic factors and LITH genes, hepatic hypersecretion, gallbladder hypomotility, rapid
phase transitions, and intestinal factors. The hypothesis proposed is that hepatic cholesterol hypersecretion into bile is the primary defect
and is the outcome in part of a complex genetic predisposition. The downstream eﬀects include gallbladder hypomotility and rapid phase
transitions. A major result of gallbladder hypomotility is alteration in the kinetics of the enterohepatic circulation of bile salts, resulting
in increased cholesterol absorption and reduced bile salt absorption that lead to abnormal enterohepatic circulation of bile salts and
diminished biliary bile salt pool size. Not only does gallbladder hypomotility facilitate cholesterol nucleation/crystallization, but also it
allows the gallbladder to retain cholesterol monohydrate crystals. Although a large number of candidate Lith genes have been identiﬁed in
mouse models, the identiﬁcation of human LITH genes and their contributions to gallstones require further investigation. Reproduced with
modiﬁcations and with permission from [48].
cholesterol. As noted, supersaturated bile is a prerequisite for
cholesterolgallstoneformation,andhypersecretionofbiliary
cholesterol is the primary metabolic abnormality responsible
for initiating cholelithiasis. However, the gallbladder and
intestine also conspire as part of a “vicious cycle” that
creates physical-chemical instabilities in bile and culminates
in the formation of cholesterol gallstones. Therefore, the
formation of cholesterol gallstones is the ﬁnal consequence
of excess secretion of cholesterol from the liver into bile
[42, 49]. It has been hypothesized that reducing cholesterol
bioavailability in the liver for biliary secretion can prevent
the formation of cholesterol gallstones and promote the
dissolution of cholesterol crystals and gallstones. This infor-
mation on the physical-chemistry of bile and the physical
forms of cholesterol carriers can help us in understanding
why ezetimibe could have a potential therapeutic eﬀect on
cholesterol gallstones.
5. Effects of Ezetimibe on the Prevention and
the Treatment of Cholesterol Gallstones
Although some, but not all, studies found that high dietary
cholesterol is associated with increased hepatic secretion
of biliary cholesterol, epidemiological investigations have
clearly demonstrated that cholesterol cholelithiasis is preva-
lent in cultures consuming a “Western” diet consisting of
high total calories, cholesterol, saturated fatty acids, reﬁned
carbohydrates, proteins, and salt, as well as low ﬁber content.
Many studies have found that the gallstone incidence in
North and South American as well as European populations
is signiﬁcantly higher than that in Asian and African
populations[15,53,54].Furthermore,severalclinicalstudies
have found an association between the increased incidence
of cholesterol gallstones in China and a “westernization” of
the traditional Chinese diet. In Japan, cholesterol cholelithi-
asis once was rare, but over the past 40 years with the
adoption of Western-type dietary habits, the incidence has
increased markedly [15, 55, 56]. Moreover, it has been
observed that there is a signiﬁcant and positive correlation
between the eﬃciency of intestinal cholesterol absorption
and the prevalence of cholesterol gallstone formation in
mice, suggesting that high eﬃciency of intestinal cholesterol
absorption and high dietary cholesterol are two independent
risk factors in the formation of cholesterol gallstones [57].
In addition, in mouse studies, targeted deletion of the acyl-
CoA:cholesterol acyltransferase gene 2 (Acat2)r e s u l t e di n
the lack of cholesterol ester synthesis in the small intes-
tine. This causes a marked reduction in intestinal choles-
terol absorption and a complete resistance to diet-induced
cholesterol gallstones [13, 15]. Furthermore, the absence
of expression of intestinal APO-B48, but not APO-B100,
reduces biliary cholesterol secretion and cholelithogenesis,
possibly by decreasing intestinal absorption and hepatic
bioavailability [15, 58]. Reduced gallstone prevalence inJournal of Lipids 7
lithogenic diet-fed apolipoprotein E knockout mice may be
explained by decreased availability of chylomicron-derived
cholesterol in the liver for biliary secretion [15, 59]. These
studies support the notion that high dietary cholesterol
through the chylomicron pathway could provide an impor-
tant source of excess cholesterol molecules for secretion into
bile, thereby inducing cholesterol-supersaturated bile and
enhancing cholelithogenesis [15].
Indeed, because biliary cholesterol hypersecretion is an
important prerequisite for cholesterol gallstone formation
[15, 42, 47], inhibition of cholesterol absorption in the
intestine, or hepatic uptake of chylomicron remnants has
become an attractive alternative to decrease biliary choles-
terol secretion and saturation [15]. Since ezetimibe signif-
icantly suppresses intestinal cholesterol absorption via the
NPC1L1 pathway [15, 60], possibly a transporter-facilitated
mechanism [15, 34], this should reduce the cholesterol
content of the liver, which in turn decreases bioavailability
of cholesterol for biliary secretion [15].
It has been found that ezetimibe induces a signiﬁcant
dose-dependent reduction in intestinal cholesterol absorp-
tion eﬃciency, coupled with a signiﬁcant dose-dependent
decrease in biliary cholesterol outputs and gallstone preva-
lence rates (Figure 3). In particular, even under high dietary
cholesterol loads, cholesterol gallstones can be prevented
by ezetimibe in C57L mice carrying the Lith1 and Lith2
genes that predispose to cholesterol stone formation [15].
Althoughezetimibesubstantiallyreducescholesterolconcen-
trations and to some extent phospholipid concentrations,
but not bile acid concentrations in gallbladder bile, all crys-
tallization pathways and phase boundaries on the bile phase
diagram are not inﬂuenced by ezetimibe [15]. Furthermore,
in company with increased doses of ezetimibe, the relative
lipid compositions of pooled gallbladder bile samples are
progressively shifted down and to the left of the phase
diagram, entering the one-phase micellar zone where there
is an abundance of unsaturated micelles, but never solid
cholesterol crystals or liquid crystals. Because the micellar
cholesterol solubility is dramatically increased in gallbladder
bile, the cholesterol molecules can be transferred from the
cholesterol monohydrate surface into unsaturated micelles.
As a result, gallstones become smaller and eventually
dissolved (Figure 4)[ 15]. This excellent physical-chemical
mechanism could explain, in part, how ezetimibe treatment
prevents cholesterol gallstone formation in mice.
Enlarged fasting gallbladder volume, together with
impaired postprandial and interdigestive gallbladder empty-
ing, is a frequent and distinctive feature in gallstone patients
[15, 61, 62], indicating that the gallbladder is another key
player in cholelithogenesis. This type of “gallbladder stasis”
provides time for nucleation of cholesterol crystals and their
aggregation into macroscopic stones [15, 42, 47, 62]. Under
conditions of cholesterol-supersaturated bile, the gallbladder
absorbs a large amount of cholesterol, thereby resulting in
the accumulation of excess cholesterol in the gallbladder
wall. Because gallbladder absorptive cells apparently cannot
assemble lipoproteins for lipid transport into plasma, the
absorbed cholesterol is converted to cholesteryl ester and
stored in the mucosa and lamina propria. As a result, excess
cholesterol in smooth muscle cells could stiﬀen sarcolemmal
membranes and decouple the G-protein-mediated signal
transduction that usually occurs when CCK binds to its
receptor, thereby further paralyzing gallbladder contractile
function and consequently impairing gallbladder emptying
function. These lithogenic eﬀects on gallbladder motility
function can be completely inhibited by ezetimibe [15, 63].
This eﬀect of ezetimibe on protecting gallbladder motility
can mostly be attributed to the desaturation of bile.
Ursodeoxycholic acid (UDCA) is currently used as a
ﬁrst-line pharmacological therapy to treat only a subgroup
of symptomatic patients with small, radiolucent cholesterol
gallstones [15, 47, 64]. Extensive clinical studies have shown
that long-term administration of UDCA promotes the disso-
lution of cholesterol gallstones and prevents the recurrence
of gallstones after extracorporeal shock wave lithotripsy
[15, 65]. However, because of a failure to titrate the dose
adequately, optimal use of UDCA is not always achieved
in clinical practice [15]. It should be pointed out that the
hydrophilic bile acid UDCA can greatly favor the formation
of vesicles in bile, which can enhance the growth of liquid
crystals on the cholesterol monohydrate surface and their
subsequent dispersion might occur during gallstone disso-
lution. Consequently, liquid crystalline dissolution allows
the transport of a great amount of cholesterol from stones
[15]. Because the cholelitholytic mechanism of ezetimibe is
totally diﬀerent from that of hydrophilic bile acids such as
UDCA, it has been proposed that a combined therapy of
ezetimibe and UDCA could be a faster means to promote
the dissolution of cholesterol gallstones, because of the
two distinct mechanisms via the formation of unsaturated
micelles by ezetimibe and a liquid crystalline mesophase by
UDCA [15], respectively.
A clinical study has been performed to examine whether
ezetimibe would reduce biliary cholesterol concentrations in
gallstone patients compared to overweight subjects without
gallstones [15]. It was observed that 30 days after starting
the medication, ezetimibe at 20mg/day signiﬁcantly reduced
cholesterolconcentrationsandcholesterolsaturationindexes
(CSIs) of gallbladder biles in gallstone patients (Table 1),
similar to the results as observed in mouse studies [15].
Consequently, cholesterol crystallization was retarded and
detection time of cholesterol monohydrate crystals was sig-
niﬁcantly delayed as analyzed by polarized light microscopy.
Although similar results between mice and gallstone patients
have been observed regarding the eﬀect of ezetimibe on the
reduction in bile cholesterol concentrations and cholesterol
crystallization, a long-term human study is needed to
observe whether ezetimibe can reduce gallstone prevalence
and completely dissolve gallstones [15].
It should be emphasized that there is a diﬀerence in
tissue distribution of NPC1L1 between mice and humans.
In mice, NPC1L1 is expressed only in the intestine, while
in humans, it can be detected in both the intestine and
liver [34]. Because of this, it has been hypothesized that
ezetimibe may have diﬀerent eﬀects on biliary cholesterol
output in humans than in mice. It has been found that
the secretion eﬃciency of biliary cholesterol is most likely
determined by the net eﬀect between eﬄux and inﬂux of8 Journal of Lipids
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Figure 3: Eﬀect of ezetimibe on the prevention of cholesterol gallstones. Ezetimibe signiﬁcantly reduced, in a dose-dependent fashion,
hepaticoutputof(a)biliarycholesteroland(b)phospholipid,butnot(c)bilesalts. ∗P<0.05, ∗∗P<0.01,and ∗∗∗P<0.001,comparedwith
mice fed the lithogenic diet and receiving no ezetimibe. (d) There is a clear dose-dependent reduction in intestinal cholesterol absorption
eﬃciency from 50 ± 6% to 4 ± 2% in chow-fed with mice, as measured by the fecal dual-isotope ratio method. (e) When doses of ezetimibe
are increased from 0 to 4mg/kg/day, gallstone prevalence rates are reduced from 80% to 10% in mice fed with the lithogenic diet for 8 weeks.
Nogallstonesarefoundinmicetreatedwithezetimibeat8mg/kg/day.(f)Therelativelipidcompositionofpooledgallbladderbilefrommice
fedwiththelithogenic diet andreceiving noezetimibe arelocated inthecentral three-phase zone, wherebile is composedofsolidcholesterol
monohydrate crystals, liquid crystals, and saturated micelles at equilibrium. In contrast, administration of the highest dose (8mg/kg/day) of
ezetimibe resulted in the relative biliary lipid composition of pooled gallbladder bile plotted in the one-phase micellar zone, even upon the
lithogenic diet feeding for 8 weeks. By phase analysis, these bile samples are composed of unsaturated micelles at equilibrium. A symbol 
represents relative lipid composition of pooled gallbladder bile at 8 weeks on the lithogenic diet supplemented with ezetimibe at 0; • 0.8; 
4;  8mg/kg/day. Reproduced with modiﬁcations and with permission from [15].
cholesterol molecules across the canalicular membrane of
the hepatocyte, which could be regulated by the ABCG5/G8-
dependent and independent pathways as well as the NPC1L1
pathway [15, 58]. Indeed, ezetimibe treatment can reduce
bile cholesterol content and CSIs and prolong detection
times of cholesterol monohydrate crystals in humans. One
possible reason for these results in humans is that because
biliary cholesterol secretion is a unique path for excretion of
cholesterol from the body in humans and animals, hepatic
ABCG5/G8 may play a stronger role in the regulation of
biliary cholesterol secretion than NPC1L1. Another possible
explanation is that in the gut-liver axis, the intestinalJournal of Lipids 9
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Figure 4: Eﬀect of ezetimibe on the dissolution of cholesterol gallstones. (a) For gallstone dissolution experiments, mice with preexisting
gallstoneswerefedachowdietalonefor8weeks,whichdoesnotresultinaspontaneousdissolutionofgallstones.Incontrast,treatmentwith
ezetimibe at 0.8 to 8mg/kg/day induces rapid dissolution of gallstones. Gallstones were completely dissolved by the highest (8mg/kg/day)
dose of ezetimibe. (b) Representative photomicrographs of mucin gel, liquid crystals, cholesterol monohydrate crystals, and gallstones as
observed in gallbladder biles at week 8 after ezetimibe treatment. All magniﬁcations are ×800, except for ezetimibe treatment at 0 and
0.8mg/kg/day, which are ×400, by polarizing light microscopy. (c) The relative lipid composition of pooled gallbladder bile from mice
fed 8 weeks with the chow diet supplemented with varying doses of ezetimibe is plotted on a condensed phase diagram. Because of a 12-
week feeding period of the lithogenic diet, the relative lipid composition of pooled gallbladder bile from mice that have formed cholesterol
gallstones is located in the central three-phase zone. Although the lithogenic diet is replaced with the chow diet for 8 weeks, the relative
biliary lipid composition of bile is still in region C, where at equilibrium the bile is composed of solid cholesterol crystals, liquid crystals, and
saturated micelles. By feeding varying doses of ezetimibe, the relative lipid composition of pooled gallbladder bile gradually shifts down and,
ﬁnally,enterstheone-phasemicellarzone.Thesealterationsexplainthatgallstonesaredissolvedthroughanunsaturatedmicellemechanism.
As y m b o l∗ represents relative lipid composition of pooled gallbladder bile from mice that have preexisting gallstones and before ezetimibe
treatment;  relative lipid composition of pooled gallbladder bile at the end of the gallstone dissolution study at week 8 of feeding the chow
diet only (control); • 0.8;  4;  8mg/kg/day of ezetimibe. Reproduced with modiﬁcations and with permission from [15].10 Journal of Lipids
Table 1: Plasma and biliary lipids before (day 0) and at day 30 after ezetimibe treatment in humans (20 mg/day)a.
Parameter Overweight subjects without gallstones Gallstone patients
Before After Before After
BMI (kg/m2) 31.5 ± 3.8 31.4 ± 3.4 27.0 ± 2.8 27.1 ± 2.3
Plasma lipid concentrations
Total Ch (mg/dL) 220 ± 41 168 ± 29b 223 ± 32 193 ± 26
LDL Ch (mg/dL) 144 ± 53 99 ± 36 145 ± 26 115 ± 23b
HDL Ch (mg/dL) 44 ± 13 37 ± 13 45 ± 11 45 ± 11
TG (mg/dL) 164 ± 88 160 ± 104 166 ± 64 165 ± 76
Biliary lipid compositions of gallbladder biles
Ch (mole%) 7.4 ± 0.7 6.8 ± 1.9 9.3 ± 1.9 7.2 ± 1.2b
PL (mole%) 20.2 ± 2.4 21.8 ± 2.5 19.3 ± 2.8 20.0 ± 3.5
BS (mole%) 72.4 ± 2.9 71.4 ± 3.9 71.4 ± 4.3 72.8 ± 4.2
Ch/PL ratio 0.37 ± 0.03 0.31 ± 0.08 0.48 ± 0.05 0.37 ± 0.06c
Ch/BS ratio 0.10 ± 0.01 0.10 ± 0.03 0.13 ± 0.03 0.10 ± 0.02
[TL] (g/dL) 5.3 ± 0.4 5.0 ± 0.9 5.5 ± 0.7 5.3 ± 0.8
CSI 1.2 ± 0.1 1.0 ± 0.2 1.6 ± 0.2 1.3 ± 0.2b
CDT (days) 6.4 ± 1.1 10.4 ± 1.1c 4.0 ± 1.2 7.0 ± 1.3c
aValues were determined from overweight subjects without gallstones (n = 5) and gallstone patients (n = 7).
bP<0.05 and cP<0.01, compared with before ezetimibe treatment (paired t test).
BMI: body mass index; TG: triglycerides; Ch: cholesterol; PL: phospholipids; BS: bile salts; [TL]: total lipid concentrations; CSI: cholesterol saturation index;
CDT: crystal detection time.
Reproduced with slightly modiﬁcations and with permission from [15].
NPC1L1 may play a signiﬁcant role in providing dietary
and reabsorbed biliary cholesterol to the body, and the
inhibition of its functions by ezetimibe signiﬁcantly reduces
cholesterol absorption. So, the bioavailability of cholesterol
from intestinal sources for biliary secretion is decreased
markedly. In contrast, inhibition of the hepatic NPC1L1 by
ezetimibe has a weak eﬀect on biliary cholesterol secretion
and CSI values [15]. More interestingly, similar to humans,
the Golden Syrian hamster displays the abundance of
NPC1L1 in the small intestine that far exceeds that in
other regions of the gastrointestinal tract such as liver and
gallbladder [66]. The tissue distribution pattern of NPC1L1
is nearly similar between hamsters and humans. It was
found that the ezetimibe-induced reduction in intestinal
cholesterol absorption is coupled with a decrease in the
absolute and relative cholesterol levels in bile in hamsters
fed a high-cholesterol diet [66]. These results are consistent
with a recent ﬁnding that ezetimibe treatment signiﬁcantly
reduces biliary cholesterol saturation in patients with gall-
stones.
Overall, ezetimibe treatment can prevent cholesterol
gallstones mainly through inhibiting intestinal cholesterol
absorption so that hepatic secretion of biliary cholesterol
is reduced, and gallbladder motility function is preserved
by desaturating bile (Figure 5). Also, ezetimibe promotes
the dissolution of cholesterol gallstones through a greater
capacity to form an abundance of unsaturated micelles.
Therefore, ezetimibe is a novel and potential cholelitholytic
agent for both preventing and treating cholesterol gallstones
[15].
6.Pathophysiology ofNonalcoholic FattyLiver
Disease(NAFLD)
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver
disease, which includes a spectrum of hepatic pathology
ranging from simple triglyceride accumulation in hepato-
cytes (hepatic steatosis) to hepatic steatosis with inﬂamma-
tion (steatohepatitis), ﬁbrosis, and cirrhosis in the absence of
alcoholabuseandothercauses[67–69].NAFLDischaracter-
ized pathologically by macrovesicular steatosis, mild diﬀuse
lobular mixed acute and chronic inﬂammation, perivenular
and zone 3 perisinusoidal collagen deposition, hepatocyte
ballooning, poorly formed Mallory-Denk bodies, glycogen
nuclei in periportal hepatocytes, lobular lipogranulomas,
and PAS-diastase-resistant Kupﬀer cells [70, 71].
NAFLD was once proposed to be the result of two
distinct but related “hits” to the hepatocyte [72, 73]. The
ﬁrst “hit” is the development of lipid accumulation and
hepatic steatosis because of an imbalance of hepatic lipid
metabolism, which leads to either excessive lipid inﬂux,
decreasedlipidclearance,orboth[70].Atthispoint,steatosis
is potentially reversible and does not necessarily induce
permanent hepatic injury. Although it is less common and
occurs in approximately 5% of individuals with steatosis,
the second “hit” is more virulent, being an inﬂammatory
process that is induced probably by oxidative stress, lipid
peroxidation, and cytokine action [74]. The resulting lobular
inﬂammation causes ballooning degeneration and perisinu-
soidal ﬁbrosis, which promote apoptosis, and hepatocellular
death. These alterations eventually induce scarring andJournal of Lipids 11
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Figure 5: Pathways underlying the absorption of cholesterol from the intestinal lumen and its delivery to the liver. High dietary cholesterol
delivery through the chylomicron pathway could provide an important source of excess cholesterol molecules for hepatic secretion into
bile, thereby inducing cholesterol-supersaturated bile and enhancing cholesterol gallstone formation. Ezetimibe signiﬁcantly suppresses
cholesterol absorption from the small intestine via the Niemann-Pick C1-like 1 (NPC1L1) pathway, possibly by a transporter-facilitated
mechanism. This eﬀect of ezetimibe could signiﬁcantly diminish the cholesterol content of the liver, which in turn remarkably decreases
bioavailability of cholesterol for hepatic secretion into bile. ABCG5/G8: ATP-binding cassette (transporters) G5 and G8; ACAT2: acyl-
CoA:cholesterol acyltransferase isoform 2; APO-B48: apolipoprotein B48; MTTP: microsomal triglyceride transfer protein. See text for
details.
progression to nonalcoholic steatohepatitis (NASH) [75].
However, many studies have been unable to prove that either
oxidant stress or lipid peroxidation is necessary for the
development of steatohepatitis in humans.
Recently, the lipotoxicity model of NASH pathogenesis
has emerged based on evidence showing that triglyceride
often accumulates in the liver as a parallel rather than
pathogenic process during lipotoxic hepatocellular injury
(Figure 6)[ 51]. Thus, it has been hypothesized that metabo-
lites of unesteriﬁed fatty acids play a critical role in inducing
lipotoxic injury in the liver. The generation of lipotoxic
metabolites of fatty acids typically occurs in parallel with the
accumulation of triglyceride droplets (steatosis), resulting
in a phenotype recognized as NASH, where steatosis and
featuresofcellularinjuryarepresenttogether[51].Metabolic
abnormalities predisposing to lipotoxic injury include an
increased supply or impaired disposal of unesteriﬁed fatty
acids. More importantly, insulin resistance could play a
central role in these processes by allowing unsuppressed
lipolysis in adipocytes resulting in an excessive ﬂow of fatty
acids from adipose tissues and also impairing peripheral
glucose disposal [51]. De novo lipogenesis in the liver using
excessive dietary carbohydrate as a substrate for fatty acid
synthesis is also a signiﬁcant contributor to the burden of
saturated fatty acids in the liver. Fatty acid disposal in the
liver occurs through oxidative pathways and through the
formation of triglyceride which is either stored temporarily
as lipid droplets or secreted as VLDL [51]. Additional
factors, including oxidative stress, mitochondrial dysfunc-
tion, gut-derived lipopolysaccharide and adipocytokines,
may promote further hepatocellular damage [76, 77]. These
processes can lead to inﬂammation, necrosis, apoptosis and
ﬁbrogenesis, which may ultimately lead to cirrhosis, liver
failure, hepatocellular carcinoma and death [78].
7. PotentialTherapeutic Effects of
EzetimibeonNAFLD
Although the role of dietary fat in the pathogenesis of
NAFLD continues to be investigated, evidence from animal
studies supports the concept that fat overconsumption plays
an important role in the etiology of hepatic steatosis [79].
It has been found that feeding a high-fat diet can induce
a signiﬁcant accumulation of lipids in the liver of animals
such as mice and rats [80]. In humans, a large amount of
dietary fat could result in the accumulation of triglyceride
in the liver, but stable isotope studies found that up to only
15% of lipids accumulated in the liver are derived directly
from dietary fat [81, 82]. In contrast, a low-carbohydrate
diet, which is otherwise rich in protein and fat, has been
used as treatment for NAFLD [83]. Furthermore, long-term
overconsumption of fat could increase risk for obesity and
insulin resistance, which enhances susceptible to NAFLD
[84].
Indeed, mice and rats develop hepatic steatosis in
response to a high-fat diet and their livers are enlarged
and appear grossly pale. Histopathological studies from
these livers reveal that hepatocytes are ﬁlled with multi-
locular droplets of varying sizes (Figure 7)[ 52]. Strikingly,12 Journal of Lipids
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Figure 6: Potential therapeutic eﬀects of ezetimibe on nonalcoholic fatty liver disease and steatohepatitis (NAFLD and NASH). On the
basis of the lipotoxicity model of NAFLD and NASH [51], it has been proposed that metabolites of unesteriﬁed fatty acids may induce
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Figure 7: Histological characterization of the hepatic response to ezetimibe in mice fed a chow versus a lithogenic diet for 4 weeks. The liver
samples from mice fed with diﬀerent diets and treated with or without ezetimibe were isolated and subjected to histological analysis. Panels
(a)–(c) show representative liver histology with hematoxylin-eosin staining and panels (d)–(f) show Oil Red O staining. (a) and (d) Mice
fed with the chow diet. (b) and (e) Mice fed with the lithogenic diet without ezetimibe. (c) and (f) Mice fed eith the lithogenic diet with
ezetimibe.Thelithogenicdietinducedasigniﬁcantaccumulationoftriglycerideandcholesterylesterintheliveraswellashepatocytedamage
and inﬂammation. Interestingly, ezetimibe treatment markedly reduced the accumulation of lipids and prevented hepatic inﬂammation.
Reproduced with modiﬁcations and with permission from [52].Journal of Lipids 13
thesediet-inducedpathologicalabnormalitiesarecompletely
absent in livers not only from ezetimibe-treated mice, but
also from NPC1L1 deﬁcient mice [79]. In addition, no signs
of inﬂammatory cell inﬁltration are found in these livers.
Hepatic concentrations of both triglyceride and cholesteryl
ester are signiﬁcantly reduced in ezetimibe-treated mice
compared with chow-fed control mice [79].
Although a high-fat diet may promote fat accumulation
in the liver by simply providing more substrate for triglyc-
eride synthesis, an important mechanism whereby a high-
fat diet may drive hepatic steatosis is by causing selective
insulin resistance [79, 85]. The increased circulating insulin
fails to suppress hepatic gluconeogenesis but can promote
hepatic lipogenesis. In contrast, ezetimibe treatment could
prevent diet-induced hepatic steatosis, weight gain, and
insulin resistance [79]. These alterations are associated with
reduced circulating insulin levels, hepatic de novo fatty acid
synthesis, and hepatic levels of mRNAs for lipogenic genes
including glucokinase, an enzyme critical in conversion of
glucose to fat. Because elevated blood insulin increases
hepatic lipogenic gene expression via transcription factors
such as SREBP-1c [16, 86, 87] and glucokinase is an
important mediator in this lipogenic pathway [16, 88], eze-
timibe treatment may protect against diet-induced hepatic
steatosis by reducing hepatic lipogenesis, mostly through
preventing diet-induced insulin resistance and the associated
hyperinsulinemia.
Because excessive amounts of cholesterol are lipogenic
through activation of LXR by its metabolites [16, 89, 90],
reduced intestinal cholesterol absorption by ezetimibe could
signiﬁcantly decrease cholesterol content in the liver. This
may prevent diet-induced hepatic steatosis in part by reduc-
ing cholesterol-dependent LXR activation in the liver [16].
Nevertheless, ezetimibe treatment indeed plays a signif-
icant role in preventing diet-induced fatty liver in animals
such as mice and rats; however, its therapeutic eﬀect on
NAFLD needs to be further investigated and proven in
humans.
8. FutureResearch Directionsand
ClinicalApplications
Ezetimibe is a highly potential and selective cholesterol
absorption inhibitor that prevents absorption of cholesterol
from dietary and biliary sources by suppressing uptake and
transport of cholesterol through the enterocytes. Although
there is clear evidence showing that ezetimibe can inhibit
cholesterol absorption through the NPC1L1 pathway, careful
and systematic studies are needed to conﬁrm whether
ezetimibe could reduce intestinal absorption of fatty acids
in animal models by direct measurement of their absorption
and lymphatic transport and studies need to be undertaken
in humans by a balance method of intestinal fatty acid
absorption. Because of signiﬁcantly reduced absorption of
intestinal cholesterol and fatty acids, the physical structure
of chylomicrons and their metabolism in adipose tissues
and liver could be inﬂuenced by ezetimibe treatment. To
evaluate treatment duration, clinical response rates and the
overall cost-beneﬁt analysis on cholesterol gallstones and
NAFLD, long-term human studies are needed. Similar to
atherosclerosis, the risk for cholesterol gallstone formation
and NAFLD increases with dyslipidemia, hyperinsulinemia,
obesity, diabetes, sedentary lifestyle, and aging. It is highly
likely that the long-term administration of ezetimibe may
beneﬁt this group of subjects who could have a high
predisposition to cholesterol gallstones and NAFLD.
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